UBS moved Siegfried Holding AG to the sidelines on Tuesday, stripping the stock of its "buy" rating and setting a new 12-month price target of CHF80, down from CHF120. The 33% reduction reflects UBS's reassessment of the company’s near-term growth trajectory and risk profile, driven by slower capacity ramp-up timelines, volatility in demand from a single top-10 customer and a lower-than-anticipated immediate impact from a recently closed U.S. drug substance acquisition.
As of June 15, Siegfried shares were trading at CHF72.95, placing the company's market capitalization at CHF3.30 billion.
"We view the current risk/reward as more balanced," UBS analysts wrote, adding that "downside risk to consensus near-term" was a primary consideration in their decision to step back from an outright buy recommendation.
UBS lowered its diluted earnings-per-share forecasts for FY26-FY28 by an average of 7%. For FY26 specifically, the broker trimmed its EPS estimate to CHF4.11 from CHF4.30. In addition to the earnings cuts, UBS reduced its assumptions for organic sales growth and EBITDA expansion: organic sales growth for FY26-30 was lowered to roughly 6.5% from 7.3%, while the expected EBITDA compound annual growth rate was pared to 11% from 12%.
The updated CHF80 price target follows three specific adjustments to UBS’s discounted cash flow model. UBS said weaker earnings explain roughly 7% of the reduction; an increase in the weighted average cost of capital accounts for another 18% after WACC was raised by 60 basis points to 7.2%; and more conservative long-term assumptions comprise the remaining 8% of the downward revision. UBS also reduced its terminal growth assumption to 2.0% from 2.5%.
For FY26, UBS projects Siegfried will generate CHF1.42 billion in revenue, a 7% increase year-on-year, along with core EBITDA of CHF340 million and an EBITDA margin of 23.9%, up 90 basis points versus the prior year. Net earnings for FY26 are forecast at CHF179 million.
UBS expects a material skew in sales between the first and second halves of FY26, forecasting a 42/58 split. The broker anticipates flat local-currency growth in H1, translating to a 2.8% decline when measured in Swiss francs for that period.
A critical short-term headwind highlighted by UBS is demand volatility from a single top-10 customer, which the broker estimates could impact revenue in the mid double-digit CHF million range. UBS noted that a large customer order that could materially affect FY26 revenues remained unconfirmed at the time of its analysis. The firm also cited overcapacity in the sterile fill-and-finish segment as an additional source of uncertainty.
The U.S. drug substance acquisition, consolidated on May 1, is expected by UBS to contribute CHF124 million in sales and CHF30 million in core EBITDA for FY26, equating to about 6% accretion on both metrics for the year under UBS’s assumptions.
On free cash flow, UBS anticipates negative FCF through FY26, with a return to positive FCF beginning in FY27. The improvement is expected to be supported by a decline in capital expenditure intensity to the low-teens as a percentage of sales, down from 16% in FY25.
In valuation terms, UBS calculates Siegfried will trade at approximately 12 times FY26 EV/EBITDA, a discount to the European CDMO peer median of roughly 18 times. UBS said this valuation gap is "justified given its lower growth and margin profile."
This reassessment from UBS tightens near-term expectations for Siegfried across revenue, margins and cash flow, placing a greater emphasis on the timing of capacity builds, customer order visibility and the integration impact of recent acquisitions.